Verena Zuber

Verena Zuber

Auto-generated profile, based on publicly available information

Verena Zuber

Imperial College London

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2018 in Annual Review of Genomics and Human Genetics
Verified
Journal Article
Open access
SBStephen Burgess
Stephen Burgess
CFChristopher N. Foley
Christopher N. Foley
VZVerena Zuber
Verena Zuber
An observational correlation between a suspected risk factor and an outcome does not necessarily imply that interventions on levels of the risk factor will have a causal impact on the outcome (correlation is not causation). If genetic variants associated with the risk factor are also associated with the outcome, then this increases the plausibility that the risk factor is a causal determinant of the outcome. However, if the genetic variants in the analysis do not have a specific biological link to the risk factor, then causal claims can be spurious. We review the Mendelian randomization paradigm for making causal inferences using genetic variants. We consider monogenic analysis, in which genetic variants are taken from a single gene region, and polygenic analysis, which includes variants from multiple regions. We focus on answering two questions: When can Mendelian randomization be used to make reliable causal inferences, and when can it be used to make relevant causal inferences?

7 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
VZVerena Zuber
Verena Zuber
JCJohanna Maria Colijn
Johanna Maria Colijn
CKCaroline Klaver
Caroline Klaver
SBStephen Burgess
Stephen Burgess
Modern high-throughput experiments provide a rich resource to investigate causal determinants of disease risk. Mendelian randomization (MR) is the use of genetic variants as instrumental variables to infer the causal effect of a specific risk factor on an outcome. Multivariable MR is an extension of the standard MR framework to consider multiple potential risk factors in a single model. However, current implementations of multivariable MR use standard linear regression and hence perform poorly with many risk factors. Here, we propose a two-sample multivariable MR approach based on Bayesian model averaging (MR-BMA) that scales to high-throughput experiments. In a realistic simulation study, we show that MR-BMA can detect true causal risk factors even when the candidate risk factors are highly correlated. We illustrate MR-BMA by analysing publicly-available summarized data on metabolites to prioritise likely causal biomarkers for age-related macular degeneration.

7 January 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MCMacTel Consortium
MacTel Consortium
LLLuca A. Lotta
Luca A. Lotta
MPMaik Pietzner
Maik Pietzner
ISIsobel D. Stewart
Isobel D. Stewart
LWLaura B. L. Wittemans
Laura B. L. Wittemans
CLClaudia Langenberg
Claudia Langenberg

25 September 2017 in Genetic Epidemiology
Verified
Journal Article
Open access
PDF file
SBStephen Burgess
Stephen Burgess
VZVerena Zuber
Verena Zuber
EVElsa Valdes‐Marquez
Elsa Valdes‐Marquez
BSBenjamin B Sun
Benjamin B Sun
JHJemma C Hopewell
Jemma C Hopewell
Mendelian randomization uses genetic variants to make causal inferences about the effect of a risk factor on an outcome. With fine‐mapped genetic data, there may be hundreds of genetic variants in a single gene region any of which could be used to assess this causal relationship. However, using too many genetic variants in the analysis can lead to spurious estimates and inflated Type 1 error rates. But if only a few genetic variants are used, then the majority of the data is ignored and estimates are highly sensitive to the particular choice of variants. We propose an approach based on summarized data only (genetic association and correlation estimates) that uses principal components analysis to form instruments. This approach has desirable theoretical properties: it takes the totality of data into account and does not suffer from numerical instabilities. It also has good properties in simulation studies: it is not particularly sensitive to varying the genetic variants included in the analysis or the genetic correlation matrix, and it does not have greatly inflated Type 1 error rates. Overall, the method gives estimates that are less precise than those from variable selection approaches (such as using a conditional analysis or pruning approach to select variants), but are more robust to seemingly arbitrary choices in the variable selection step. Methods are illustrated by an example using genetic associations with testosterone for 320 genetic variants to assess the effect of sex hormone related pathways on coronary artery disease risk, in which variable selection approaches give inconsistent inferences.

25 December 2018 in JAMA
Verified
Journal Article
Open access
PDF file
LLLuca A. Lotta
Luca A. Lotta
LWLaura B. L. Wittemans
Laura B. L. Wittemans
VZVerena Zuber
Verena Zuber
ISIsobel D. Stewart
Isobel D. Stewart
SSStephen J. Sharp
Stephen J. Sharp
CLClaudia Langenberg
Claudia Langenberg
The distribution of body fat is associated with the propensity of overweight individuals to manifest insulin resistance and its associated metabolic and cardiovascular complications.1-5 The waist-to-hip ratio (WHR) is a widely used, convenient, and robustly validated indicator of fat distribution and is linked to the risk of type 2 diabetes and coronary disease independently of body mass index (BMI, calculated as weight in kilograms divided by height in meters squared).1-5 This observation has been used to infer that accumulation of fat in the abdominal cavity is an independent causal contributor to cardiometabolic disease. While many studies support this assertion and plausible mechanisms have been proposed, WHR can also be increased by a reduction in its denominator, the hip circumference. Evidence from several different forms of partial lipodystrophy6,7 and functional studies of peripheral adipose storage compartments8-10 suggests that a primary inability to expand gluteofemoral or hip fat can also underpin subsequent cardiometabolic disease risk. Emerging evidence from the analysis of common genetic variants associated with greater insulin resistance but lower levels of hip fat suggests that similar mechanisms may also be relevant to the general population.11-14

10 January 2018 in BMJ
Verified
Journal Article
Open access
PDF file
TSTyler M Seibert
Tyler M Seibert
CFChun Chieh Fan
Chun Chieh Fan
YWYunpeng Wang
Yunpeng Wang
VZVerena Zuber
Verena Zuber
RKRoshan Karunamuni
Roshan Karunamuni
ADAnders M Dale
Anders M Dale
Objectives To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age. Design Analysis of genotype, PCa status, and age to select single nucleotide polymorphisms (SNPs) associated with diagnosis. These polymorphisms were incorporated into a survival analysis to estimate their effects on age at diagnosis of aggressive PCa (that is, not eligible for surveillance according to National Comprehensive Cancer Network guidelines; any of Gleason score ≥7, stage T3-T4, PSA (prostate specific antigen) concentration ≥10 ng/L, nodal metastasis, distant metastasis). The resulting polygenic hazard score is an assessment of individual genetic risk. The final model was applied to an independent dataset containing genotype and PSA screening data. The hazard score was calculated for these men to test prediction of survival free from PCa. Setting Multiple institutions that were members of international PRACTICAL consortium. Participants All consortium participants of European ancestry with known age, PCa status, and quality assured custom (iCOGS) array genotype data. The development dataset comprised 31 747 men; the validation dataset comprised 6411 men. Main outcome measures Prediction with hazard score of age of onset of aggressive cancer in validation set. Results In the independent validation set, the hazard score calculated from 54 single nucleotide polymorphisms was a highly significant predictor of age at diagnosis of aggressive cancer (z=11.2, P98th centile) were compared with those with average scores (30th-70th centile), the hazard ratio for aggressive cancer was 2.9 (95% confidence interval 2.4 to 3.4). Inclusion of family history in a combined model did not improve prediction of onset of aggressive PCa (P=0.59), and polygenic hazard score performance remained high when family history was accounted for. Additionally, the positive predictive value of PSA screening for aggressive PCa was increased with increasing polygenic hazard score. Conclusions Polygenic hazard scores can be used for personalised genetic risk estimates that can predict for age at onset of aggressive PCa.